MCID: PLS025
MIFTS: 51

Plasmablastic Lymphoma

Categories: Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Plasmablastic Lymphoma

MalaCards integrated aliases for Plasmablastic Lymphoma:

Name: Plasmablastic Lymphoma 49 55 69
Immunoblastic Large-Cell Lymphoma 69
Pbl 55

Classifications:



External Ids:

Orphanet 55 ORPHA289666
UMLS via Orphanet 70 C3472614
ICD10 via Orphanet 33 C83.3

Summaries for Plasmablastic Lymphoma

NIH Rare Diseases : 49 Plasmablastic lymphoma is an aggressive form of non-Hodgkin lymphoma. Although the condition most commonly occurs in the oral cavity, it can be diagnosed in many other parts of the body such as the gastrointestinal tract, lymph nodes, and skin. The exact underlying cause of plasmablastic lymphoma is poorly understood; however, it is often associated with suppression of the immune system (i.e. HIV infection, immunosuppressive therapy). There is currently no standard therapy for plasmablastic lymphoma. Treatment usually consists of chemotherapy with or without radiation therapy and hematopoietic stem cell transplantation. Last updated: 1/18/2016

MalaCards based summary : Plasmablastic Lymphoma, also known as immunoblastic large-cell lymphoma, is related to b-cell lymphomas and lymphoma, hodgkin, classic. An important gene associated with Plasmablastic Lymphoma is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are Gastric cancer and MicroRNAs in cancer. The drugs Cyclophosphamide and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are cellular and cardiovascular system

Wikipedia : 72 Plasmablastic lymphoma is a type of large B-cell lymphoma, recognized in the WHO 2008... more...

Related Diseases for Plasmablastic Lymphoma

Diseases related to Plasmablastic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphomas 30.0 BCL6 CDKN2A MS4A1
2 lymphoma, hodgkin, classic 29.9 BCL6 MS4A1 PTPRC
3 richter's syndrome 29.7 CD38 NOTCH1
4 mantle cell lymphoma 29.5 BCL6 CDKN2A MTOR
5 leukemia, chronic lymphocytic 28.9 ABCB1 BCL6 CD38 MS4A1 NOTCH1 PTPRC
6 caspase 8 deficiency 11.0
7 lymphoma 11.0
8 heart lymphoma 10.5 BCL6 PTPRC
9 nodular lymphocyte predominant hodgkin lymphoma 10.5 BCL6 PTPRC
10 testicular lymphoma 10.5 BCL6 PTPRC
11 primary cutaneous anaplastic large cell lymphoma 10.4 MUC1 PTPRC
12 epidural neoplasm 10.4 BCL6 PTPRC
13 mucinous cystadenocarcinoma 10.4 MUC1 PTPRC
14 lymphosarcoma 10.4 BCL6 PTPRC
15 lymphatic system cancer 10.4 BCL6 PTPRC
16 multicentric castleman disease 10.4 ABCB1 BCL6
17 peripheral t-cell lymphoma 10.4 BCL6 MS4A1
18 dendritic cell tumor 10.3 MUC1 PTPRC
19 primitive neuroectodermal tumor of the cervix uteri 10.3 DES PTPRC
20 spindle cell thymoma 10.3 DES MUC1
21 parachordoma 10.3 DES MUC1
22 ossifying fibromyxoid tumor 10.3 DES MUC1
23 spindle cell rhabdomyosarcoma 10.3 DES MUC1
24 biphasic synovial sarcoma 10.3 DES MUC1
25 myxofibrosarcoma 10.3 DES MUC1
26 syringocystadenoma papilliferum 10.3 DES MUC1
27 reticulosarcoma 10.3 BCL6 MUC1 PTPRC
28 syringoma 10.3 DES MUC1
29 proximal spinal muscular atrophy 10.3 DES MUC1
30 perivascular epithelioid cell tumor 10.3 DES MUC1
31 spindle cell sarcoma 10.2 DES MUC1
32 mesenchymal chondrosarcoma 10.2 DES MUC1
33 malignant peritoneal mesothelioma 10.2 CDKN2A MUC1
34 gamma heavy chain disease 10.2 CD38 PTPRC
35 b cell prolymphocytic leukemia 10.2 CD38 MS4A1
36 primary central nervous system lymphoma 10.2 BCL6 CDKN2A
37 mucinous bronchioloalveolar adenocarcinoma 10.2 CDKN2A MUC1
38 gastrointestinal carcinoma 10.2 ABCB1 MUC1
39 endometrial mucinous adenocarcinoma 10.2 CDKN2A MUC1
40 sarcomatoid mesothelioma 10.2 CDKN2A MUC1
41 well-differentiated liposarcoma 10.2 CDKN2A MUC1
42 vulvar seborrheic keratosis 10.2 CDKN2A MTOR
43 plasma cell neoplasm 10.2 CD38 PTPRC
44 lymphoblastic lymphoma 10.2 BCL6 NOTCH1 PTPRC
45 hemangiopericytoma, malignant 10.1 DES MUC1
46 meningeal melanocytoma 10.1 CDKN2A MUC1
47 mature b-cell neoplasm 10.1 BCL6 CD38 PTPRC
48 crohn's disease 10.1
49 benign mesothelioma 10.1 DES MUC1
50 reticulum cell sarcoma 10.1 DES MUC1 PTPRC

Graphical network of the top 20 diseases related to Plasmablastic Lymphoma:



Diseases related to Plasmablastic Lymphoma

Symptoms & Phenotypes for Plasmablastic Lymphoma

MGI Mouse Phenotypes related to Plasmablastic Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.01 PTPRC CDKN2A DES MTOR BCL6 NOTCH1
2 cardiovascular system MP:0005385 9.98 CDKN2A DES ABCB1 MTOR BCL6 NOTCH1
3 endocrine/exocrine gland MP:0005379 9.97 PTPRC VDR ABCB1 MTOR BCL6 NOTCH1
4 hematopoietic system MP:0005397 9.97 CDKN2A PTPRC VDR ABCB1 MS4A1 MTOR
5 homeostasis/metabolism MP:0005376 9.91 CDKN2A PTPRC DES ABCB1 MTOR BCL6
6 immune system MP:0005387 9.81 CDKN2A PTPRC ABCB1 MS4A1 MTOR BCL6
7 liver/biliary system MP:0005370 9.35 PTPRC CDKN2A ABCB1 BCL6 NOTCH1
8 muscle MP:0005369 9.1 CDKN2A DES MTOR BCL6 NOTCH1 VDR

Drugs & Therapeutics for Plasmablastic Lymphoma

Drugs for Plasmablastic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 450)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
3
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
9
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
10
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
11
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
12
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
13
Idarubicin Approved Phase 3 58957-92-9 42890
14
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
15
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
16
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 460612 4053
17
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
18
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
19
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
20
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
21
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
22
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
23
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
24
Bleomycin Approved, Investigational Phase 3,Phase 1,Phase 2 11056-06-7 5360373
25
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
26
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
27
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
28
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
29
Ofloxacin Approved Phase 3 82419-36-1 4583
30
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
31
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
32
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
33
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
34
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
35
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
36
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
37
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
38
Morphine Approved, Investigational Phase 3 57-27-2 5288826
39
Captopril Approved Phase 3 62571-86-2 44093
40
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
41
Ribavirin Approved Phase 3 36791-04-5 37542
42
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
43
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-23-7 657311 5754
44
Ephedrine Approved Phase 3 299-42-3 9294
45
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
46
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
47
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
48
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2 3375-50-6 598
49
Vancomycin Approved Phase 3 1404-90-6 14969 441141
50
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283

Interventional clinical trials:

(show top 50) (show all 545)

# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
6 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
7 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
8 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
9 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
10 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
11 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
12 Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma Completed NCT00002565 Phase 3 CHOP regimen;cisplatin;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;idarubicin;ifosfamide;mesna;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
13 Combination Chemotherapy in Treating Patients With Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
14 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
15 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
18 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
20 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
21 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
25 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
26 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00003150 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
31 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
32 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
33 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
34 Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Completed NCT00005867 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
35 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
36 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
37 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
38 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
39 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
40 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
41 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
42 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
43 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
44 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
45 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
46 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
47 Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma Completed NCT00002618 Phase 3 cytarabine;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;vincristine sulfate
48 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
49 Rituxan vs Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (BMT CTN 0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
50 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid

Search NIH Clinical Center for Plasmablastic Lymphoma

Genetic Tests for Plasmablastic Lymphoma

Anatomical Context for Plasmablastic Lymphoma

MalaCards organs/tissues related to Plasmablastic Lymphoma:

38
Bone, Bone Marrow, B Cells, T Cells, Liver, Kidney, Lymph Node

Publications for Plasmablastic Lymphoma

Articles related to Plasmablastic Lymphoma:

(show top 50) (show all 304)
# Title Authors Year
1
Orbital plasmablastic lymphoma. ( 29375870 )
2018
2
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. ( 29303024 )
2018
3
Successful cord blood transplantation for an HIV-negative patient with refractory plasmablastic lymphoma. ( 28293711 )
2017
4
11C-Methionine-Avid Plasmablastic Lymphoma. ( 28825948 )
2017
5
Mediastinal syndrome from plasmablastic lymphoma in human immunodeficiency virus and human herpes virus 8 negative patient with polycythemia vera: a case report. ( 28320457 )
2017
6
HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy. ( 28592757 )
2017
7
Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma. ( 28831541 )
2017
8
MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma. ( 29296171 )
2017
9
Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. ( 28963907 )
2017
10
A case of HIV-negative plasmablastic lymphoma of the bone marrow with a unique immunophenotype. ( 28588836 )
2017
11
Primary cutaneous plasmablastic lymphoma presenting as perineal ulcero-proliferative growth in a human immunodeficiency virus-seropositive patient. ( 27779143 )
2017
12
Plasmablastic lymphoma with unfavorable chromosomal abnormalities related to plasma cell myeloma: A borderline case between plasmablastic lymphoma and plasmablastic plasma cell myeloma ( 28679965 )
2017
13
Intraocular Plasmablastic Lymphoma in a HIV Patient. ( 28929004 )
2017
14
Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy. ( 28782668 )
2017
15
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. ( 28993364 )
2017
16
Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: Experience at a regional cancer centre in India. ( 28702410 )
2017
17
Oral plasmablastic lymphoma as the first manifestation of AIDS. ( 29267464 )
2017
18
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. ( 29387498 )
2017
19
Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review. ( 29090101 )
2017
20
Long-Term Survival of Primary Intracranial Plasmablastic Lymphoma: Case Report and Review of the Literature. ( 27794513 )
2017
21
Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets. ( 28860565 )
2017
22
Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. ( 28249941 )
2017
23
Pediatric plasmablastic lymphoma: Diagnostic and therapeutic dilemma. ( 28631667 )
2017
24
A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy. ( 28095384 )
2017
25
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? ( 29081245 )
2017
26
Unusual presentation of plasmablastic lymphoma involving ovarian mature cystic teratoma: a case report. ( 29187222 )
2017
27
Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. ( 27687004 )
2017
28
Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review. ( 28207555 )
2017
29
Plasmablastic Lymphoma. ( 28746329 )
2017
30
Plasmablastic lymphoma presenting as exophytic skin lesions. ( 28700895 )
2017
31
Plasmablastic lymphoma: Review of 60 Chinese cases and prognosis analysis. ( 28248855 )
2017
32
Primary testicular plasmablastic lymphoma: unique case in a 30 year old. ( 27121529 )
2016
33
Plasmablastic Lymphoma of Small Intestine: A Rare Case Report with Review of Literature. ( 27408374 )
2016
34
Human immunodeficiency virus associated plasmablastic lymphoma: A case report. ( 27795651 )
2016
35
Clinical Characteristics and Prognostic Factors of Plasmablastic Lymphoma Patients: Analysis of 135 Patients from the Lysa Group. ( 28031174 )
2016
36
Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. ( 26801792 )
2016
37
Plasmablastic lymphoma exclusively involving bones mimicking osteosarcoma in an immunocompetent patient: A case report. ( 27428232 )
2016
38
A Rare Case of Plasmablastic Lymphoma Mimicking Adenocarcinoma of the Sigmoid Colon. ( 27657558 )
2016
39
Primary cutaneous plasmablastic lymphoma revealing clinically unsuspected HIV infection. ( 27579749 )
2016
40
Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis. ( 27684979 )
2016
41
Retracted: Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions. ( 27110244 )
2016
42
Ileo-ileal Intussusception and Bowel Obstruction Caused by Plasmablastic Lymphoma of Small Bowel- A Rare Entity in Rare Location. ( 27134931 )
2016
43
Clinicopathologic characteristics of HIV/AIDS-related plasmablastic lymphoma. ( 27164966 )
2016
44
Richter Syndrome With Plasmablastic Lymphoma at Primary Diagnosis: A Case Report With a Review of the Literature. ( 27801729 )
2016
45
Coexistence of intestinal Kaposi sarcoma and plasmablastic lymphoma in an HIV/AIDS patient: case report and review of the literature. ( 27034819 )
2016
46
Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings. ( 27324386 )
2016
47
Aberrant expression of T-cell marker CD7 in HIV negative intestinal plasmablastic lymphoma. ( 27788919 )
2016
48
Plasmablastic lymphoma of the gastrointestinal tract: A rare entity with a dismal prognosis. ( 28485344 )
2016
49
Plasmablastic Lymphoma Mimicking Acute Pancreatitis. ( 27034868 )
2016
50
Impact of highly active antiretroviral therapy in the development and remission of oral plasmablastic lymphoma. ( 27966518 )
2016

Variations for Plasmablastic Lymphoma

Expression for Plasmablastic Lymphoma

Search GEO for disease gene expression data for Plasmablastic Lymphoma.

Pathways for Plasmablastic Lymphoma

GO Terms for Plasmablastic Lymphoma

Cellular components related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 8.92 ABCB1 CD38 NOTCH1 PTPRC

Biological processes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.67 BCL6 CDKN2A NOTCH1 VDR
2 cell cycle arrest GO:0007050 9.58 CDKN2A MTOR NOTCH1
3 B cell proliferation GO:0042100 9.43 MS4A1 PTPRC
4 negative regulation of transcription, DNA-templated GO:0045892 9.35 BCL6 CD38 CDKN2A NOTCH1 VDR
5 negative regulation of cell-matrix adhesion GO:0001953 9.32 BCL6 CDKN2A
6 positive regulation of keratinocyte differentiation GO:0045618 9.26 NOTCH1 VDR
7 somatic stem cell division GO:0048103 9.16 CDKN2A NOTCH1
8 positive regulation of B cell proliferation GO:0030890 8.8 BCL6 CD38 PTPRC

Sources for Plasmablastic Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....